Needham & Company
View Older Stories
-
Intercept Pharmaceuticals (ICPT) PT Lowered to $100 at Needham & Company
-
Intercept Pharma (ICPT) Prices Offerings of Common Stock and Convertible Senior Notes due 2026
-
Intercept Pharmaceuticals Announces Pricing of Offerings of Common Stock and Convertible Senior Notes due 2026
-
Intercept Pharmaceuticals (ICPT) Bullish View Reiterated at Needham & Company on Positive Positive Phase 3 REGENERATE NASH Trial
-
Pre-Open Stock Movers 1/24: (AZPN) (XLNX) (LRCX) Higher; (BGG) (MKC) (UMPQ) Lower (more...)
-
Needham & Company Upgrades Intercept Pharmaceuticals (ICPT) to Buy
-
Pre-Open Movers 08/06: (SEAS) (VTL) (CTWS) Higher; (OVID) (BID) (PX) Lower (more...)
-
Intercept to Present at Upcoming Conference
-
Intercept Pharma (ICPT) Impacts On Sales In PBC Should be Minimal - Needham
-
Intercept to Present at Upcoming Conference
-
Needham & Company Downgrades Intercept Pharmaceuticals (ICPT) to Hold
-
Intercept Pharma (ICPT): AASLD Meeting Takeaway - Needham
-
Needham & Company Weighs in on Brexit Biotech Impact (ACAD) (GILD0 (ICPT) (SGEN)
-
Streetinsider.com's Hot Lunchtime Reads 5/31: (AAPL) (MON) (VRX) (ICPT)
-
Needham & Company Positive on Intercept Pharma (ICPT); Expects Initial Ocaliva Uptake to be 'Strong'
-
Needham & Company Reiterates Buy on Intercept Pharma (ICPT) Following Positive FDA Panel Vote on Obeticholic Acid
-
Intercept Pharmaceuticals (ICPT) Bullish View Reiterated at Needham & Company Following Analyst Meeting
-
Needham & Company Reiterates Buy on Intercept (ICPT) Following Q3 Update
-
Needham & Company Reiterates Bullish View on Intercept (ICPT) Despite Narrow-Miss in OCA Phase 2 Japanese NASH Trial
-
Intercept's (ICPT) Rolling NDA, MAA Submissions for OCA Appear on Track; Needham & Company Affirms at 'Buy'
-
Intercept (ICPT) Bullish Stance Reiterated at Needham & Company Amid AASLD Industry Colloquium Review
-
Intercept Pharmaceuticals Announces Completion of Public Offering and Exercise of Option to Purchase Additional Shares
-
Intercept Pharma (ICPT) 1M Stock Offering Prices at $176/Share
-
Intercept Pharmaceuticals Announces Pricing of Public Offering
-
Intercept Pharmaceuticals (ICPT) Bullish Stance Reiterated at Needham & Company Following AASLD Meeting
-
Pre-Open Stock Movers 11/07: (MITK) (RMTI) (SHLD) Higher; (SLXP) (ICPT) (GUID) Lower (more...)
-
Notable Analyst Rating Changes 07/01: (NFLX) (FOLD) (NBR) Upgraded; (GS) (MNKD) (URBN) Downgraded
-
Notable Analyst Rating Changes 05/15: (PLUG) (PTX) (TWTR) Upgraded; (BMY) (HII) (CXP) Downgraded
-
Intercept Pharmaceuticals (ICPT) Bullish Stance Reiterated at Needham & Company Despite OCA NDA/MAA Push Back
-
Intercept Pharmaceuticals (ICPT) Bullish Stance Reiterated at Needham & Company
-
Intercept Pharma (ICPT) Prices 1M Common Offering at $320/Share
-
Intercept Pharmaceuticals Announces Pricing of Public Offering
-
Intercept Pharma (ICPT) to Offer 1M Shares
-
Intercept Pharmaceuticals Announces Proposed Public Offering of Common Stock
-
Intercept (ICPT) Target Lifted at Needham & Company on Positive Phase 3 Results for OCA in PBC
-
Intercept Pharmaceuticals (ICPT) Target Lifted to $320 at Needham & Company
-
Pre-Open Stock Movers 1/9: (ICPT) (CRDC) (F) Higher; (YRCW) (FDO) (PIR) Lower (more...)
-
Intercept Pharma (ICPT) Prices 1.73M Common Offering at $33.01/Share
-
Needham & Company Lifts PT on Intercept Pharmaceuticals (IPCT) with OCA Phase 3 POISE Trial Ahead of Schedule
-
Notable Analyst Rating Changes 11/12: (SQNM) (DIS) (KLAC) Upgraded; (GRMN) (JCP) (SD) Downgraded
-
BMO Capital Starts Intercept Pharmaceuticals (ICPT) at Outperform
-
Needham & Company Starts Intercept Pharmaceuticals (ICPT) at Buy
-
Intercept Pharmaceuticals (ICPT) IPO Trades 26% Higher
-
Intercept Pharmaceuticals (ICPT) Files $75M IPO